This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Cameron Durrant
Chairman and CEO at Humanigen, Inc.


Dr. Durrant is an entrepreneur, board member, C-level executive, former big pharma executive and an MD by original training. He is Chairman and CEO of Humanigen, a public company developing monoclonal antibodies for COVID-19, CAR-T, GvHD, oncology and other serious and life-threatening conditions.
His specialty is both start-ups and turnarounds, including brands and business units as well as companies. He has served as board chairman, lead independent director and operated as CEO or interim CEO, as well as acting CFO and acting CMO for both private and public companies.

He has been involved in 4 exits, including the $640MM acquisition of Hi-Tech Pharmacal by Akorn and the subsequent divestment of ECR Pharmaceuticals by Akorn to Valeant. He has raised several hundred million dollars from a variety of sources and has been an executive at several blue-chip big pharmacos and held business unit P+L and staff roles, both in the US and globally.

He is a founding director of a private nanotech oncology company and a board member of a private medical device company.

He is a prior regional winner of the Ernst and Young ‘Entrepreneur of the Year’ award, named in the PharmaVoice 2005, 2006, 2007 and 2010 list of one of the ‘100 most inspiring people in the pharmaceutical industry’.
Dr. Durrant earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxford, UK.

Agenda Sessions

  • Case Study: Accelerating Manufacturing for Investigational COVID-19 Therapeutic Candidate Lenzilumab to Prevent and Treat Cytokine Storm